RRML - Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology – case report
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- March 2024 -
 
Association of betaine-homocys... 2
Improvement of total antioxida... 1
Tissue protection immunohistoc... 1
Anticoagulant mechanisms are m... 1
Changes in the erythrocyte mem... 1
Severe adverse reactions to bl... 1
Screening for common cystic fi... 1
Laboratory techniques in multi... 1
Interdisciplinary correlations... 1
Platelet function monitoring t... 1

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 10(1)/2008
XML
TXT

Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology – case report

Anca Bacârea, Bogdana Dorcioman, Minodora Dobreanu, Galafteon Oltean, Smaranda Demian, Anamaria Rusu, Maria T. Dogaru, Camil Eugen Vari


Abstract:

The treatment of acute myeloid leukemia specific includes antracyclinic compounds and cytrabine; the limitation factor of clinical efficacy is dose-related drug toxicity. Beside cytotoxic specific adverse reactions, the claimed medication presents a target cardiac toxicity. This paper presents a clinical case, the relationship between medication and iatrogenic risks and also patient prognosis.

Keywords: acute myeloid leukemia,treatment,prognostic

 
  PDF Download full text PDF
(917 KB)
     
 
How to cite
Bacârea A, Dorcioman B, Dobreanu M, Oltean G, Demian S, Rusu A, et al. Acute myeloid leukemia treatment – between therapeutic benefit and iatrogenic pathology – case report. Rev Romana Med Lab. 2008;10(1):33-8